Nice review. At this point IPIX should continue on its prudent course of carefully and thoughtfully engaging the FDA. An example of aggressive promotion drawing the ire of the FDA can be seen with Cytodyn.
The FDA's letter to Cytodyn was a warning to all pharma companies.
The fallout from the FDA slap down continues to plague the company. Last week Cytodyn received subpoenas from the SEC and DOJ regarding Leronlimab's promotion.